These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 25299893)

  • 21. Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through protein kinase B-mediated vesicle transport.
    Shinohara M; Nakamura M; Masuda H; Hirose J; Kadono Y; Iwasawa M; Nagase Y; Ueki K; Kadowaki T; Sasaki T; Kato S; Nakamura H; Tanaka S; Takayanagi H
    J Bone Miner Res; 2012 Dec; 27(12):2464-75. PubMed ID: 22806988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):8-9. PubMed ID: 24870874
    [No Abstract]   [Full Text] [Related]  

  • 23. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
    Certal V; Carry JC; Halley F; Virone-Oddos A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Karlsson A; Charrier V; Delorme C; Rak A; Abecassis PY; Amara C; Vincent L; Bonnevaux H; Nicolas JP; Mathieu M; Bertrand T; Marquette JP; Michot N; Benard T; Perrin MA; Lemaitre O; Guerif S; Perron S; Monget S; Gruss-Leleu F; Doerflinger G; Guizani H; Brollo M; Delbarre L; Bertin L; Richepin P; Loyau V; Garcia-Echeverria C; Lengauer C; Schio L
    J Med Chem; 2014 Feb; 57(3):903-20. PubMed ID: 24387221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discussion: Managing Risk When Using Idelalisib.
    Coutre SE; Burger JA; Pagel JM
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):13. PubMed ID: 27168205
    [No Abstract]   [Full Text] [Related]  

  • 25. The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion.
    Luk SK; Piekorz RP; Nürnberg B; Tony To SS
    Eur J Cancer; 2012 Jan; 48(1):149-57. PubMed ID: 22079609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3Kα inhibitors.
    Wu P; Su Y; Liu X; Zhang L; Ye Y; Xu J; Weng S; Li Y; Liu T; Huang S; Yang B; He Q; Hu Y
    Eur J Med Chem; 2011 Nov; 46(11):5540-8. PubMed ID: 21945250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infectious bursal disease virus activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway by interaction of VP5 protein with the p85α subunit of PI3K.
    Wei L; Hou L; Zhu S; Wang J; Zhou J; Liu J
    Virology; 2011 Aug; 417(1):211-20. PubMed ID: 21723579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Straying from the target.
    The Lancet Haematology
    Lancet Haematol; 2016 May; 3(5):e205. PubMed ID: 27132690
    [No Abstract]   [Full Text] [Related]  

  • 29. Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
    Pepper C; Buggins AG; Jones CH; Walsby EJ; Forconi F; Pratt G; Devereux S; Stevenson FK; Fegan C
    Leukemia; 2015 Mar; 29(3):744-7. PubMed ID: 25349153
    [No Abstract]   [Full Text] [Related]  

  • 30. Recent therapeutic advances in the treatment of colorectal cancer.
    Ciombor KK; Wu C; Goldberg RM
    Annu Rev Med; 2015; 66():83-95. PubMed ID: 25341011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [CAL-101,a novel agent of targeted therapy in hematological malignancies].
    Li CJ; Zhang Q; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):530-3. PubMed ID: 24763037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
    Castillo JJ; Furman M; Winer ES
    Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First PI3k inhibitor launches into crowded hematology markets.
    Morrison C
    Nat Biotechnol; 2014 Oct; 32(10):963-4. PubMed ID: 25299893
    [No Abstract]   [Full Text] [Related]  

  • 34. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 35. Idelalisib has activity in mantle cell lymphoma.
    Cancer Discov; 2014 May; 4(5):OF8. PubMed ID: 24795031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
    Shiver MB; Mahmoud F; Gao L
    N Engl J Med; 2015 Oct; 373(16):1580-2. PubMed ID: 26466009
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.